SWM
SRNE

Salvus Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Salvus Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,911
Closed -$36.2K – 108
2022
Q4 		$36.2K Hold
40,911
– – 0.03% 95
2022
Q3 		$64K Hold
40,911
– – 0.06% 96
2022
Q2 		$82K Buy
+40,911
New +$70.7K 0.07% 97

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Salvus Wealth Management's SRNE Position: Q1 2023 in Review

Salvus Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 40,911 shares — an estimated $36.2K sold.

Salvus Wealth Management first reported a position in SRNE in Q2 2022 and held it in 3 quarters. The position peaked at $82K in Q2 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Salvus Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Salvus Wealth Management sold 40,911 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $36.2K.
  • Salvus Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2022 and held it in 3 quarters.
  • Salvus Wealth Management's Sorrento Therapeutics, Inc. position peaked at $82K in Q2 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Salvus Wealth Management's 13F filing for Q1 2023, filed 11 Apr 2023.